AnPac Bio-Medical Science Co. Ltd.

5.00-0.6000-10.71%Vol 115.78K1Y Perf -38.66%
Apr 16th, 2021 16:00 DELAYED
BID5.00 ASK5.33
Open5.62 Previous Close5.60
Pre-Market- After-Market-
 - -  - -%
Target Price
8.00 
Analyst Rating
— — 0.00
Potential %
60.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap56.01M 
Earnings Rating
Price Range Ratio 52W %
20.69 
Earnings Date
17th May 2021

Today's Price Range

5.005.62

52W Range

3.1512.09

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-13.34%
1 Month
-30.07%
3 Months
-12.89%
6 Months
42.86%
1 Year
-38.66%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANPC5.00-0.6000-10.71
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date17th May 2021
Estimated EPS Next Report-
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume115.78K
Shares Outstanding11.20M
Trades Count555
Dollar Volume467.36K
Avg. Volume747.23K
Avg. Weekly Volume75.27K
Avg. Monthly Volume135.23K
Avg. Quarterly Volume859.61K

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) stock closed at 5 per share at the end of the most recent trading day (a -10.71% change compared to the prior day closing price) with a volume of 2.01M shares and market capitalization of 56.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 111 people. AnPac Bio-Medical Science Co. Ltd. CEO is Chris Chang Yu.

The one-year performance of AnPac Bio-Medical Science Co. Ltd. stock is -38.66%, while year-to-date (YTD) performance is -5.66%. ANPC stock has a five-year performance of %. Its 52-week range is between 3.15 and 12.09, which gives ANPC stock a 52-week price range ratio of 20.69%

AnPac Bio-Medical Science Co. Ltd. currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 116.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -146.22%, a ROC of -252.95% and a ROE of -329.66%. The company’s profit margin is -%, its EBITDA margin is -691.70%, and its revenue ttm is $554.67 Thousand , which makes it $0.05 revenue per share.

Of the last four earnings reports from AnPac Bio-Medical Science Co. Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AnPac Bio-Medical Science Co. Ltd.’s next earnings report date is 17th May 2021.

The consensus rating of Wall Street analysts for AnPac Bio-Medical Science Co. Ltd. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AnPac Bio-Medical Science Co. Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AnPac Bio-Medical Science Co. Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AnPac Bio-Medical Science Co. Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.19, ATR14 : 0.81, CCI20 : -151.50, Chaikin Money Flow : -0.70, MACD : -0.17, Money Flow Index : 11.29, ROC : -10.87, RSI : 59.17, STOCH (14,3) : 0.00, STOCH RSI : 0.60, UO : 30.07, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AnPac Bio-Medical Science Co. Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

AnPac Bio-Medical Science Co. Ltd.

AnPac Bio-Medical Science Co Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative, patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.

CEO: Chris Chang Yu

Telephone: +86 57820516666

Address: 801 Bixing Street, Lishui 323006, , CN

Number of employees: 111

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

74%26%

Bearish Bullish

56%44%

Bearish Bullish

65%35%

News

Stocktwits